Phase 2 study of talabostat, a small molecule inhibitor of dipeptidyl peptidases (DPP), administered in combination with pembrolizumab in patients with small cell neuroendocrine prostate cancer.

The maximum difference was observed for interferon (IFN)-gamma (15.1-fold vs 7.4-fold induction of IFN-gamma in responders vs non-responders, respectively), although this did not reach statistical significance in this small sample set ( figure 2 , online supplemental table 1 ).

also in 111,027 other papers